| CSGP |
Report |
Revenue |
IN-LINE |
pred ~$930M vs. cons $928.9M |
MEDIUM |
| CSGP |
Report |
Adjusted EBITDA |
BEAT |
pred ~$180M vs. cons $173.0M |
MEDIUM |
| CSGP |
Report |
Net new bookings |
BEAT |
pred ~$90M vs. cons $88.4M |
LOW |
| CSGP |
Guide |
Q3 2026 Revenue |
LOWER |
guide ~$955M-$965M vs. cons $968.6M |
LOW |
| CSGP |
Guide |
Q3 2026 Adjusted EBITDA |
LOWER |
guide ~$215M-$225M vs. cons $223.9M |
LOW |
| CSGP |
Guide |
FY26 Revenue |
UNCHANGED |
guide $3.78B-$3.82B vs. cons $3.799B |
MEDIUM |
| CSGP |
Guide |
FY26 Adjusted EBITDA |
UNCHANGED |
guide $780M-$820M vs. cons $805.2M |
MEDIUM |
| CSGP |
Return |
Day-1 residual (stock − beta × S&P 500) |
-5.5% |
— |
LOW |
| CSGP |
Return |
5-day cumulative residual |
-6.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — Q3 estimate pressure |
LOW |